Nicotinamide Riboside (NR) Dosage: What the Trials Used

Most of the supplements in the longevity aisle ask you to guess at a dose, because the human dosing data simply doesn't exist — the numbers on the label were borrowed from animal studies or invented whole. Nicotinamide riboside (NR) is a refreshing exception. It has actual human randomized controlled trials that used defined daily doses, then measured whether blood NAD+ went up and whether people tolerated it. That gives you something solid to anchor to: not a personalized "optimal" number, but a real record of what was studied in people and what happened.

This page reports what the NR trials actually used — no more, no less. It's a description of the published doses, not a prescription. The honest summary up front: research doses ran from a few hundred milligrams up to about 1,000 mg/day, the popular label doses (250–300 mg, the dose in products like Tru Niagen) sit at the lower end of that range, and there's no human evidence that pushing higher buys you a bigger real-world benefit.

What the human NR trials actually used

Two well-run, placebo-controlled trials anchor the NR dosing picture, and they bracket the range nicely.

In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, participants took NIAGEN (nicotinamide riboside chloride) at a defined daily dose over an extended period. The trial was specifically built to test long-term safety and metabolism, and across that dosing window NR was well tolerated and raised blood NAD+ without major safety signals ¹. That's the lower-to-middle part of the studied range, tested for tolerability over time rather than for a single big number.

At the higher end, a chronic-supplementation trial in healthy middle-aged and older adults used roughly 1,000 mg/day of NR. Again it was well tolerated, and again it durably elevated blood NAD+ over weeks of dosing — clean target engagement at a dose about three to four times the typical capsule ².

So the human evidence isn't a single magic number. It's a range — from a few hundred milligrams up to about 1,000 mg/day — across which NR reliably does the one thing it's proven to do: raise the NAD+ biomarker, while staying well tolerated.

Label doses are lower than some research doses

Here's the part that surprises people. The dose in the most common branded NR products — 250 to 300 mg/day, which is what you'll find in Tru Niagen and similar capsules — sits at the bottom of the studied range, well below the ~1,000 mg/day used in the higher-dose trial ².

That gap is real, and the obvious instinct is to "correct" it by taking three or four capsules to match the highest research dose. But that instinct assumes more NR equals more benefit, and that assumption isn't supported. Both trials confirmed the same core result — NAD+ goes up and the supplement is tolerated — and the higher-dose study didn't demonstrate that the extra milligrams translated into a bigger outcome you'd actually feel. It demonstrated a bigger biomarker move at most, and even the lower-dose work already moves that biomarker reliably ¹².

More isn't proven better

This is the central honest point about NR dosing. The trials prove that NR at these doses raises NAD+ and is safe. They do not prove a dose-response for any benefit that matters to a buyer — more energy, slower aging, a longer healthspan. Raising the biomarker harder is not the same as delivering a harder-hitting result, because the link between "NAD+ went up more" and "you're measurably better off" has not been established in humans.

So escalating from a 300 mg label dose to 1,000 mg is, on the current evidence, paying more to move a number further — not a validated route to a better outcome. The safety record at the higher dose is reassuring ², but reassuring safety is permission, not a reason. If you want the deeper version of why the biomarker-to-benefit leap is a marketing inference, our nicotinamide riboside benefits page lays out exactly what is and isn't proven.

What about long-term "optimal" dosing?

The most honest thing to say is that nobody knows the optimal long-term NR dose, because the trials weren't designed to find it. They tested whether defined doses were safe and raised NAD+ over their study windows — not which dose, taken for years, best improves hard health outcomes. There is no published head-to-head establishing a long-term optimum, no validated maintenance dose, and no human data on dosing over the multi-year horizons people actually supplement on.

That uncertainty argues for restraint, not escalation. The lower, label-range dose has a clean tolerability record and already engages the target; the higher dose adds cost and a bigger biomarker move without a proven payoff. Anchoring to what was studied — rather than to what a calculator or a forum recommends — is the defensible move.

The honest bottom line on NR dosing

• •The NR trials used defined daily doses, roughly a few hundred mg up to ~1,000 mg/day, and at those doses NR reliably raised blood NAD+ and was well tolerated ¹².
• •Common label doses (250–300 mg, e.g. Tru Niagen) sit at the low end of the studied range — lower than the ~1,000 mg/day used in the higher-dose trial ².
• •More isn't proven better: the trials show safety and a biomarker rise, not a dose-response for any felt benefit. Long-term optimal dosing is unestablished.

Treat these as the doses that were studied, not a personalized recommendation. For how to pick a product at a sensible dose, see our Tru Niagen review; for how NR's dosing compares to its main rival precursor, our NMN vs NR comparison lines them up. Before you commit, check the nicotinamide riboside side effects page, the broader NAD+ and NMN dosage guide, and our calculators and tools to compare doses for yourself.